ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

VAD

May 3, 2018
A somewhat delayed publication of a 2016 paper that discusses important trends in cardiac transplanation in the light of increasing use of ECMO.
April 3, 2018
Gosev and colleagues evaluated the baseline characteristics and outcomes in 156 patients from 12 centers who survived at least four years on left ventricular assist device (LVAD) support. Among this group of patients, mean survival was 7.1 years (95% CI 6.7 to 7.5 years).
March 12, 2018
An interesting two-year report from the MOMENTUM 3 randomized controlled trial comparison of HeartMate 3 and II, the analysis performed by Abbott. Although stroke and reoperation were clearly lower with the latest technology, reflected in the lower LDH measurements, there was bafflingly no improvement in survival.  
February 8, 2018
Schweiger and colleagues retrospectively analyzed stroke rate for patients under 19 years old in the European Registry for Patients with Mechanical Circulatory Support database.
January 2, 2018
A sobering editorial, read last May at the AATS, that discusses at length the ethics of ventricular assist as a super expensive therapy seen from the principle of fairness.
December 22, 2017
Bansal and colleagues describe survival after left ventricular assist device placement for patients with end-stage renal disease (ESRD), based on Medicare claims associated with data in the United States Renal Data System registry. Prognosis for these patients was very poor compared to patients without ESRD, particularly in the short-term.
November 16, 2017
The incoming issue of the Journal comes with an interesting group of papers revolving around a provocative topic: work from Seattle on the absence of predictive value of standard pulmonary function tests in LVAD surgery.  Vivek Rao takes the opportunity to present his thoughts in this brief editorial, the important central message of which cannot be
October 27, 2017
A measured succinct reflection on MagLev and older ventricular assist devices, on the occasion of a relevant 'expert opinion' paper on the topic.
October 12, 2017
The Impella RP device was approved by the FDA for use as a temporary percutaneous assist for  the right ventricle, as announced by Abiomed.  Use is approved for up to 14 days for a variety of indications including post MI, heart transplant, open heart surgery, or right heart failure after LVAD implant.
October 6, 2017
A stimulating editorial triggered by tri-species autopsy work on angiodysplasia potentially attributable to continuous-flow LVAD. Dr Birks discusses the findings and appears open to the suggestion that LVAD per se is a cause of gastrointestinal angiodysplasia and thence  bleeding, as opposed to the anticoagulation for LVAD.

Pages